Meeting
2022 ASCO Annual Meeting
Outcomes of recurrent and metastatic endometrial cancer (RMEC) treated with systemic progestins.
Authors
Anjali Kulkarni
Ottawa Hospital Research Institute, Ottawa, ON, Canada
Anjali Kulkarni , Natalie Andrews Wright , Alyssa N Forget , Ranjeeta Mallick , Tim O Ramsay , Johanne I Weberpals
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5585)
DOI
10.1200/JCO.2022.40.16_suppl.5585
Abstract #
5585
Poster Bd #
461
Abstract Disclosures
Similar Posters
First Author: B.J. Rimel
Poster
2023 ASCO Annual Meeting
A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer.
First Author: Bradley Corr
Poster
2023 ASCO Annual Meeting
TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC).
First Author: Alessandro Santin
Poster
2023 ASCO Annual Meeting
Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer.
First Author: Drew W. Rasco